Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision…
Palleon Pharmaceuticals Showcases First-in-Class B7-H3–Targeted Sialidase at AACR 2026 Palleon Pharmaceuticals has unveiled new preclinical findings and announced the initiation of a first-in-human clinical trial for its novel oncology candidate…
Neurogene Announces Christy Shafer as Chief Commercial Officer and Appoints Christine Mikail, J.D., to Its Board Neurogene Inc. has announced key leadership additions as it advances its mission to develop…
Pulse Biosciences Highlights nPulse™ Technology Presentation at Heart Rhythm Society 2026 Annual Meeting Pulse Biosciences has announced a strong presence at the upcoming Heart Rhythm Society Annual Meeting, where it…
Bicycle Therapeutics Shares Pipeline Update on Nuzefatide Pevedotin and EphA2 Programs at AACR 2026 Bicycle Therapeutics has unveiled a comprehensive set of updates from its EphA2-targeting oncology pipeline at the…
RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in…
FDA Prioritizes Review of KEYTRUDA® and KEYTRUDA QLEX™ Combinations with Padcev® for Cisplatin-Eligible Muscle-Invasive Bladder Cancer Patients Merck & Co., known as MSD outside the United States and Canada, has…
Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs)…
Lundbeck highlights AAN 2026 data showing real-world improvements in migraine-related cognitive symptoms with VYEPTI® (eptinezumab-jjmr) Lundbeck has presented new real-world data from its ongoing INFUSE study at the American Academy…
Zai Lab shares preclinical data showing ZL-1503 delivers rapid itch relief and reduces inflammation in atopic diseases Zai Lab Limited has announced promising new preclinical findings for ZL-1503, its internally…
Agenus highlights durable survival and immune reprogramming in PD-1 refractory gastroesophageal cancer with Botensilimab combo Agenus Inc., a company focused on advancing immuno-oncology innovation, has reported new clinical findings from…
Zai Lab reports strong, rapid brain metastasis responses with Zocilurtatug Pelitecan in SCLC and other neuroendocrine cancers Zai Lab Limited has unveiled compelling new clinical and preclinical data highlighting the…